HYFTHealthcare · BiotechnologyThe 3 Wall Street analysts covering MindWalk Holdings Corp. hold a median 12-month price target of $5 — +342.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores MindWalk Holdings Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (23): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on HYFT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +342.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 16 Apr 2026 | Jones Trading | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
HYFT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, MindWalk Holdings Corp. returned −29.8% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 36% of US stocks
Cheaper than 8% of US stocks
Cheaper than 77% of US stocks
Higher than 70% of US stocks
Higher than 13% of US stocks
Higher than 74% of US stocks
Higher than 12% of US stocks
Higher than 6% of US stocks
Higher than 11% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MindWalk Holdings Corp. has a market value of $53.2M and an enterprise value of $35.1M.
Revenue in the twelve months to 30 Apr 2026: $15.6M. The latest quarter grew 21.3% year on year.
Net income over the same four quarters: −$13.9M, a −89.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.30.
Free cash flow in the twelve months to 30 Apr 2026: −$12.9M, after $398K of capital spending.
Trailing P/E: −3.7×; forward P/E: −4.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MindWalk Holdings Corp. employs 74 people — $210K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MindWalk Holdings Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MindWalk announced that Thomas Lynch, PhD, departed the company and ceased serving as Chief Business Officer, effective October 16, 2026. CEO and President Jennifer Bath said the company’s commercial priorities remain unchanged.
Why it matters — HYFT watchers may note the change in leadership alongside management’s statement that commercial priorities are unchanged.
MindWalk published a white paper reporting that LensAI screened 890,634 public antibody sequences in 4 hours and 41 minutes on specified Amazon EC2 instances. The company said the run delivered up to 43% lower cost per sequence than a comparable Intel setup running identical code.
Why it matters — The reported scale, runtime, and comparative cost provide HYFT watchers with details about LensAI’s performance in antibody immunogenicity screening.
MindWalk Holdings announced three senior appointments to strengthen its Boston-based development leadership as its pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director of Antigen Discovery & Protein Engineering, and Joanne Lim, PhD, joins as Director of Preclinical Development.
Why it matters — The appointments add development leadership as HYFT progresses its pipeline toward preclinical efficacy studies.
MindWalk said enterprise AI’s emerging ontology layer does not capture biological function and that life sciences needs its own biological context layer. It described ReefIQ as a governed, model-agnostic representation of what biology does.
Why it matters — HYFT watchers may note the company’s positioning of ReefIQ as a life-sciences-specific layer alongside broader enterprise AI ontology efforts.
MindWalk Holdings Corp. announced the appointment of Kim Remizowski as an independent director to its Board of Directors, effective September 29, 2026. He will serve on the Audit Committee and the Compensation, Nomination and Governance Committee, and has been determined to qualify as an audit committee financial expert under Nasdaq rules.
Why it matters — The addition of a qualified independent director strengthens the company's board governance and audit oversight.
The 3 Wall Street analysts covering MindWalk Holdings Corp. have a median 12-month price target of $5, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering MindWalk Holdings Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MindWalk Holdings Corp. 50 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, MindWalk Holdings Corp. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +342.5% from the last close, and Ticker Nerd's factor model ranks MindWalk Holdings Corp. 50 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MindWalk Holdings Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HYFT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.
MindWalk Holdings Corp. returned -29.8% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
MindWalk Holdings Corp. operates as a bio-native AI company.
The most recent item we track (Business Wire, 22 Oct 2026): "MindWalk Holdings Corp. Announces Leadership Update". MindWalk announced that Thomas Lynch, PhD, departed the company and ceased serving as Chief Business Officer, effective October 16, 2026. CEO and President Jennifer Bath said the company’s commercial priorities remain unchanged.
MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company is headquartered in Austin, Texas.
CEO Dr. Jennifer Lynne Bath Ph.D. · 74 employees · United States · https://www.mindwalkai.com
